Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 90

1.

Impact of dose adaptations following voriconazole therapeutic drug monitoring in pediatric patients.

Lempers VJ, Meuwese E, Mavinkurve-Groothuis AM, Henriet S, van der Sluis IM, Hanff LM, Warris A, Koch BCP, Brüggemann RJ.

Med Mycol. 2019 Feb 13. doi: 10.1093/mmy/myz006. [Epub ahead of print]

PMID:
30759261
2.

Pharmacology, Pharmacokinetics and Pharmacodynamics of Eculizumab, and Possibilities for an Individualized Approach to Eculizumab.

Wijnsma KL, Ter Heine R, Moes DJAR, Langemeijer S, Schols SEM, Volokhina EB, van den Heuvel LP, Wetzels JFM, van de Kar NCAJ, Brüggemann RJ.

Clin Pharmacokinet. 2019 Feb 13. doi: 10.1007/s40262-019-00742-8. [Epub ahead of print] Review.

PMID:
30758736
3.

Pharmacokinetics and probability of target attainment for micafungin in normal-weight and morbidly obese adults.

Wasmann RE, Smit C, Ter Heine R, Koele SE, van Dongen EPH, Wiezer RMJ, Burger DM, Knibbe CAJ, Brüggemann RJM.

J Antimicrob Chemother. 2019 Jan 15. doi: 10.1093/jac/dky554. [Epub ahead of print]

PMID:
30649375
4.

Ciprofloxacin penetration into infected hepatic cysts in autosomal dominant polycystic kidney disease: a case report.

Bernts LHP, Wallenburg E, de Jonge HJM, Schaap B, Kusters R, Overtoom TTC, Brüggemann RJM, Drenth JPH, Lantinga MA.

J Antimicrob Chemother. 2019 Mar 1;74(3):829-830. doi: 10.1093/jac/dky456. No abstract available.

PMID:
30452619
5.

The potential impact of hematocrit correction on evaluation of tacrolimus target exposure in pediatric kidney transplant patients.

Schijvens AM, van Hesteren FHS, Cornelissen EAM, Bootsma-Robroeks CMHHT, Brüggemann RJM, Burger DM, de Wildt SN, Schreuder MF, Ter Heine R.

Pediatr Nephrol. 2019 Mar;34(3):507-515. doi: 10.1007/s00467-018-4117-x. Epub 2018 Oct 30.

PMID:
30374607
6.

Pharmacokinetics of extended dose intervals of micafungin in haematology patients: optimizing antifungal prophylaxis.

Muilwijk EW, Maertens JA, van der Velden WJFM, Ter Heine R, Colbers A, Burger DM, Andes D, Theunissen K, Blijlevens NMA, Brüggemann RJM.

J Antimicrob Chemother. 2018 Nov 1;73(11):3095-3101. doi: 10.1093/jac/dky324.

PMID:
30137340
7.

European guidelines for primary antifungal prophylaxis in adult haematology patients: summary of the updated recommendations from the European Conference on Infections in Leukaemia.

Maertens JA, Girmenia C, Brüggemann RJ, Duarte RF, Kibbler CC, Ljungman P, Racil Z, Ribaud P, Slavin MA, Cornely OA, Peter Donnelly J, Cordonnier C; European Conference on Infections in Leukaemia (ECIL), a joint venture of the European Group for Blood and Marrow Transplantation (EBMT), the European Organization for Research and Treatment of Cancer (EORTC), the Immunocompromised Host Society (ICHS) and; European Conference on Infections in Leukaemia (ECIL), a joint venture of the European Group for Blood and Marrow Transplantation (EBMT), the European Organization for Research and Treatment of Cancer (EORTC), the Immunocompromised Host Society (ICHS) and the European LeukemiaNet (ELN) .

J Antimicrob Chemother. 2018 Dec 1;73(12):3221-3230. doi: 10.1093/jac/dky286.

PMID:
30085172
8.

Cancer prevention by aspirin in children with Constitutional Mismatch Repair Deficiency (CMMRD).

Leenders EKSM, Westdorp H, Brüggemann RJ, Loeffen J, Kratz C, Burn J, Hoogerbrugge N, Jongmans MCJ.

Eur J Hum Genet. 2018 Oct;26(10):1417-1423. doi: 10.1038/s41431-018-0197-0. Epub 2018 Jun 14. Review.

PMID:
29904176
9.

Caspofungin dosage adjustments are not required for patients with Child-Pugh B or C cirrhosis.

Gustot T, Ter Heine R, Brauns E, Cotton F, Jacobs F, Brüggemann RJ.

J Antimicrob Chemother. 2018 Sep 1;73(9):2493-2496. doi: 10.1093/jac/dky189.

PMID:
29860319
10.

Manual punch versus automated flow-through sample desorption for dried blood spot LC-MS/MS analysis of voriconazole.

Martial LC, van den Hombergh E, Tump C, Halmingh O, Burger DM, van Maarseveen EM, Brüggemann RJ, Aarnoutse RE.

J Chromatogr B Analyt Technol Biomed Life Sci. 2018 Jul 1;1089:16-23. doi: 10.1016/j.jchromb.2018.04.039. Epub 2018 Apr 27.

PMID:
29747155
11.

Moderate correlation between systemic IL-6 responses and CRP with trough concentrations of voriconazole.

Vreugdenhil B, van der Velden WJFM, Feuth T, Kox M, Pickkers P, van de Veerdonk FL, Blijlevens NMA, Brüggemann RJM.

Br J Clin Pharmacol. 2018 Sep;84(9):1980-1988. doi: 10.1111/bcp.13627. Epub 2018 Jun 19.

12.

Pharmacokinetics of Anidulafungin in Obese and Normal-Weight Adults.

Wasmann RE, Ter Heine R, van Dongen EP, Burger DM, Lempers VJ, Knibbe CA, Brüggemann RJ.

Antimicrob Agents Chemother. 2018 Jun 26;62(7). pii: e00063-18. doi: 10.1128/AAC.00063-18. Print 2018 Jul.

13.

The diagnosis and treatment of invasive aspergillosis in Dutch haematology units facing a rapidly increasing prevalence of azole-resistance. A nationwide survey and rationale for the DB-MSG 002 study protocol.

Schauwvlieghe AFAD, de Jonge N, van Dijk K, Verweij PE, Brüggemann RJ, Biemond BJ, Bart A, von dem Borne PA, Verbon A, van der Beek MT, Demandt AMP, Oudhuis GJ, Cornelissen JJ, van der Velden WJFM, Span LFR, Kampinga GA, Bruns AH, Vonk AG, Haas PA, Doorduijn JK, Rijnders BJA.

Mycoses. 2018 Apr 23. doi: 10.1111/myc.12788. [Epub ahead of print]

PMID:
29687483
14.

Diagnosis and management of Aspergillus diseases: executive summary of the 2017 ESCMID-ECMM-ERS guideline.

Ullmann AJ, Aguado JM, Arikan-Akdagli S, Denning DW, Groll AH, Lagrou K, Lass-Flörl C, Lewis RE, Munoz P, Verweij PE, Warris A, Ader F, Akova M, Arendrup MC, Barnes RA, Beigelman-Aubry C, Blot S, Bouza E, Brüggemann RJM, Buchheidt D, Cadranel J, Castagnola E, Chakrabarti A, Cuenca-Estrella M, Dimopoulos G, Fortun J, Gangneux JP, Garbino J, Heinz WJ, Herbrecht R, Heussel CP, Kibbler CC, Klimko N, Kullberg BJ, Lange C, Lehrnbecher T, Löffler J, Lortholary O, Maertens J, Marchetti O, Meis JF, Pagano L, Ribaud P, Richardson M, Roilides E, Ruhnke M, Sanguinetti M, Sheppard DC, Sinkó J, Skiada A, Vehreschild MJGT, Viscoli C, Cornely OA.

Clin Microbiol Infect. 2018 May;24 Suppl 1:e1-e38. doi: 10.1016/j.cmi.2018.01.002. Epub 2018 Mar 12.

PMID:
29544767
15.

Effect of Haloperidol on Survival Among Critically Ill Adults With a High Risk of Delirium: The REDUCE Randomized Clinical Trial.

van den Boogaard M, Slooter AJC, Brüggemann RJM, Schoonhoven L, Beishuizen A, Vermeijden JW, Pretorius D, de Koning J, Simons KS, Dennesen PJW, Van der Voort PHJ, Houterman S, van der Hoeven JG, Pickkers P; REDUCE Study Investigators, van der Woude MCE, Besselink A, Hofstra LS, Spronk PE, van den Bergh W, Donker DW, Fuchs M, Karakus A, Koeman M, van Duijnhoven M, Hannink G.

JAMA. 2018 Feb 20;319(7):680-690. doi: 10.1001/jama.2018.0160.

16.

Obesity and drug pharmacology: a review of the influence of obesity on pharmacokinetic and pharmacodynamic parameters.

Smit C, De Hoogd S, Brüggemann RJM, Knibbe CAJ.

Expert Opin Drug Metab Toxicol. 2018 Mar;14(3):275-285. doi: 10.1080/17425255.2018.1440287. Epub 2018 Feb 15. Review.

PMID:
29431542
17.

Clinical validation study of dried blood spot for determining everolimus concentration in patients with cancer.

Willemsen AECAB, Knapen LM, de Beer YM, Brüggemann RJM, Croes S, van Herpen CML, van Erp NP.

Eur J Clin Pharmacol. 2018 Apr;74(4):465-471. doi: 10.1007/s00228-017-2394-0. Epub 2017 Dec 8.

18.

Development and validation of an analytical method using UPLC-MS/MS to quantify everolimus in dried blood spots in the oncology setting.

Knapen LM, Beer Y, Brüggemann RJM, Stolk LM, Vries F, Tjan-Heijnen VCG, Erp NPV, Croes S.

J Pharm Biomed Anal. 2018 Feb 5;149:106-113. doi: 10.1016/j.jpba.2017.10.039. Epub 2017 Oct 29.

PMID:
29112898
19.

Isavuconazole susceptibility of clinical Aspergillus fumigatus isolates and feasibility of isavuconazole dose escalation to treat isolates with elevated MICs.

Buil JB, Brüggemann RJM, Wasmann RE, Zoll J, Meis JF, Melchers WJG, Mouton JW, Verweij PE.

J Antimicrob Chemother. 2018 Jan 1;73(1):263. doi: 10.1093/jac/dkx425. No abstract available.

PMID:
29112717
20.

Isavuconazole susceptibility of clinical Aspergillus fumigatus isolates and feasibility of isavuconazole dose escalation to treat isolates with elevated MICs.

Buil JB, Brüggemann RJM, Wasmann RE, Zoll J, Meis JF, Melchers WJG, Mouton JW, Verweij PE.

J Antimicrob Chemother. 2018 Jan 1;73(1):134-142. doi: 10.1093/jac/dkx354. Erratum in: J Antimicrob Chemother. 2018 Jan 1;73(1):263.

PMID:
29048485
21.

Itraconazole or Amphotericin B for Talaromycosis.

Brüggemann RJ, van de Veerdonk FL, Verweij PE.

N Engl J Med. 2017 Oct 5;377(14):1402-1403. doi: 10.1056/NEJMc1709123. No abstract available.

PMID:
28976857
22.

Pharmacokinetic Properties of Micafungin in Critically Ill Patients Diagnosed with Invasive Candidiasis.

Boonstra JM, van der Elst KC, Veringa A, Jongedijk EM, Brüggemann RJ, Koster RA, Kampinga GA, Kosterink JG, van der Werf TS, Zijlstra JG, Touw DJ, Alffenaar JWC.

Antimicrob Agents Chemother. 2017 Nov 22;61(12). pii: e01398-17. doi: 10.1128/AAC.01398-17. Print 2017 Dec.

23.

Clinical Pharmacokinetics and Pharmacodynamics of Micafungin.

Wasmann RE, Muilwijk EW, Burger DM, Verweij PE, Knibbe CA, Brüggemann RJ.

Clin Pharmacokinet. 2018 Mar;57(3):267-286. doi: 10.1007/s40262-017-0578-5. Review.

24.

Drug-drug interactions between triazole antifungal agents used to treat invasive aspergillosis and immunosuppressants metabolized by cytochrome P450 3A4.

Groll AH, Townsend R, Desai A, Azie N, Jones M, Engelhardt M, Schmitt-Hoffman AH, Brüggemann RJM.

Transpl Infect Dis. 2017 Oct;19(5). doi: 10.1111/tid.12751. Epub 2017 Sep 28. Review.

PMID:
28722255
25.

Flucloxacillin Results in Suboptimal Plasma Voriconazole Concentrations.

Muilwijk EW, Dekkers BGJ, Henriet SSV, Verweij PE, Witjes B, Lashof AMLO, Groeneveld GH, van der Hoeven J, Alffenaar JWC, Russel FGM, van de Veerdonk F, Brüggemann RJM.

Antimicrob Agents Chemother. 2017 Aug 24;61(9). pii: e00915-17. doi: 10.1128/AAC.00915-17. Print 2017 Sep.

26.

Dried Blood Spot Sampling for Tacrolimus and Mycophenolic Acid in Children: Analytical and Clinical Validation.

Martial LC, Hoogtanders KEJ, Schreuder MF, Cornelissen EA, van der Heijden J, Joore MA, Van Maarseveen EM, Burger DM, Croes S, Brüggemann RJM, Aarnoutse RE.

Ther Drug Monit. 2017 Aug;39(4):412-421. doi: 10.1097/FTD.0000000000000422.

PMID:
28700522
27.

Early postnatal gentamicin and ceftazidime treatment in normal and food restricted neonatal wistar rats: Implications for kidney development.

Bueters RRG, Jeronimus-Klaasen A, Brüggemann RJM, van den Heuvel LP, Schreuder MF.

Birth Defects Res. 2017 Sep 1;109(15):1228-1235. doi: 10.1002/bdr2.1071. Epub 2017 Jul 11.

PMID:
28696058
28.

A Population Pharmacokinetic Model to Predict the Individual Starting Dose of Tacrolimus Following Pediatric Renal Transplantation.

Andrews LM, Hesselink DA, van Gelder T, Koch BCP, Cornelissen EAM, Brüggemann RJM, van Schaik RHN, de Wildt SN, Cransberg K, de Winter BCM.

Clin Pharmacokinet. 2018 Apr;57(4):475-489. doi: 10.1007/s40262-017-0567-8.

29.

The role of infection models and PK/PD modelling for optimising care of critically ill patients with severe infections.

Tängdén T, Ramos Martín V, Felton TW, Nielsen EI, Marchand S, Brüggemann RJ, Bulitta JB, Bassetti M, Theuretzbacher U, Tsuji BT, Wareham DW, Friberg LE, De Waele JJ, Tam VH, Roberts JA; Infection Section for the European Society of Intensive Care Medicine, the Pharmacokinetics and Pharmacodynamics Study Group of the European Society of Clinical Microbiology and Infectious Diseases, the International Society of Anti-Infective Pharmacology and the Critically Ill Patients Study Group of European Society of Clinical Microbiology and Infectious Diseases.

Intensive Care Med. 2017 Jul;43(7):1021-1032. doi: 10.1007/s00134-017-4780-6. Epub 2017 Apr 13. Review.

PMID:
28409203
30.

Eculizumab Dosing Regimen in Atypical HUS: Possibilities for Individualized Treatment.

Volokhina E, Wijnsma K, van der Molen R, Roeleveld N, van der Velden T, Goertz J, Sweep F, Brüggemann RJ, Wetzels J, van de Kar N, van den Heuvel L.

Clin Pharmacol Ther. 2017 Oct;102(4):671-678. doi: 10.1002/cpt.686. Epub 2017 May 26.

PMID:
28295239
31.

Population Pharmacokinetic Model and Pharmacokinetic Target Attainment of Micafungin in Intensive Care Unit Patients.

Martial LC, Ter Heine R, Schouten JA, Hunfeld NG, van Leeuwen HJ, Verweij PE, de Lange DW, Pickkers P, Brüggemann RJ.

Clin Pharmacokinet. 2017 Oct;56(10):1197-1206. doi: 10.1007/s40262-017-0509-5.

32.

Dried Blood Spot sampling in psychiatry: Perspectives for improving therapeutic drug monitoring.

Martial LC, Aarnoutse RE, Mulder M, Schellekens A, Brüggemann RJM, Burger DM, Schene AH, Batalla A.

Eur Neuropsychopharmacol. 2017 Mar;27(3):205-216. doi: 10.1016/j.euroneuro.2017.01.009. Epub 2017 Jan 24. Review.

PMID:
28130001
33.

Caspofungin Population Pharmacokinetics in Critically Ill Patients Undergoing Continuous Veno-Venous Haemofiltration or Haemodiafiltration.

Roger C, Wallis SC, Muller L, Saissi G, Lipman J, Brüggemann RJ, Lefrant JY, Roberts JA.

Clin Pharmacokinet. 2017 Sep;56(9):1057-1068. doi: 10.1007/s40262-016-0495-z.

PMID:
28035589
34.

Cost Evaluation of Dried Blood Spot Home Sampling as Compared to Conventional Sampling for Therapeutic Drug Monitoring in Children.

Martial LC, Aarnoutse RE, Schreuder MF, Henriet SS, Brüggemann RJ, Joore MA.

PLoS One. 2016 Dec 12;11(12):e0167433. doi: 10.1371/journal.pone.0167433. eCollection 2016.

35.

The role of the multidisciplinary team in antifungal stewardship.

Agrawal S, Barnes R, Brüggemann RJ, Rautemaa-Richardson R, Warris A.

J Antimicrob Chemother. 2016 Nov;71(suppl 2):ii37-ii42.

PMID:
27880668
36.

Pharmacokinetics of Anidulafungin in Critically Ill Intensive Care Unit Patients with Suspected or Proven Invasive Fungal Infections.

Brüggemann RJ, Middel-Baars V, de Lange DW, Colbers A, Girbes AR, Pickkers P, Swart EL.

Antimicrob Agents Chemother. 2017 Jan 24;61(2). pii: e01894-16. doi: 10.1128/AAC.01894-16. Print 2017 Feb.

37.

A preliminary study searching for the right dose of tacrolimus in very young (≤4 years) renal transplant patients.

Martial LC, Verstegen RH, Cornelissen EA, Aarnoutse RE, Schreuder MF, Brüggemann RJ.

J Pharm Pharmacol. 2016 Nov;68(11):1366-1372. doi: 10.1111/jphp.12639. Epub 2016 Sep 27.

PMID:
27669677
38.

CYP2C19 Genotype-Dependent Pharmacokinetic Drug Interaction Between Voriconazole and Ritonavir-Boosted Atazanavir in Healthy Subjects.

Zhu L, Brüggemann RJ, Uy J, Colbers A, Hruska MW, Chung E, Sims K, Vakkalagadda B, Xu X, van Schaik RH, Burger DM, Bertz RJ.

J Clin Pharmacol. 2017 Feb;57(2):235-246. doi: 10.1002/jcph.798. Epub 2016 Aug 23.

PMID:
27432796
39.

Drug-Drug Interactions in Treatment Using Azole Antifungal Agents.

Schreuder MF, van de Kar NC, Brüggemann RJ.

JAMA. 2016 Jun 21;315(23):2622. doi: 10.1001/jama.2016.3820. No abstract available.

PMID:
27327812
40.

Antifungal therapy: drug-drug interactions at your fingertips-authors' response.

Lempers VJ, Brüggemann RJ.

J Antimicrob Chemother. 2016 Jul;71(7):2062-3. doi: 10.1093/jac/dkw159. Epub 2016 May 12. No abstract available.

PMID:
27273868
41.

Does Weight Impact Anidulafungin Pharmacokinetics?

Lempers VJ, van Rongen A, van Dongen EP, van Ramshorst B, Burger DM, Aarnoutse RE, Knibbe CA, Brüggemann RJ.

Clin Pharmacokinet. 2016 Oct;55(10):1289-1294. doi: 10.1007/s40262-016-0401-8.

42.

Inhibitory Potential of Antifungal Drugs on ATP-Binding Cassette Transporters P-Glycoprotein, MRP1 to MRP5, BCRP, and BSEP.

Lempers VJ, van den Heuvel JJ, Russel FG, Aarnoutse RE, Burger DM, Brüggemann RJ, Koenderink JB.

Antimicrob Agents Chemother. 2016 May 23;60(6):3372-9. doi: 10.1128/AAC.02931-15. Print 2016 Jun.

43.

Pharmacokinetics and target attainment of mycophenolate in pediatric renal transplant patients.

Martial LC, Jacobs BA, Cornelissen EA, de Haan AF, Koch BC, Burger DM, Aarnoutse RE, Schreuder MF, Brüggemann RJ.

Pediatr Transplant. 2016 Jun;20(4):492-9. doi: 10.1111/petr.12695. Epub 2016 Feb 29.

PMID:
26923724
44.

Dose Reduction of Caspofungin in Intensive Care Unit Patients with Child Pugh B Will Result in Suboptimal Exposure.

Martial LC, Brüggemann RJ, Schouten JA, van Leeuwen HJ, van Zanten AR, de Lange DW, Muilwijk EW, Verweij PE, Burger DM, Aarnoutse RE, Pickkers P, Dorlo TP.

Clin Pharmacokinet. 2016 Jun;55(6):723-33. doi: 10.1007/s40262-015-0347-2.

45.

Antifungal therapy: drug-drug interactions at your fingertips.

Lempers VJ, Brüggemann RJ.

J Antimicrob Chemother. 2016 Feb;71(2):285-9. doi: 10.1093/jac/dkv350. Epub 2015 Nov 8.

PMID:
26553846
46.

International expert opinion on the management of infection caused by azole-resistant Aspergillus fumigatus.

Verweij PE, Ananda-Rajah M, Andes D, Arendrup MC, Brüggemann RJ, Chowdhary A, Cornely OA, Denning DW, Groll AH, Izumikawa K, Kullberg BJ, Lagrou K, Maertens J, Meis JF, Newton P, Page I, Seyedmousavi S, Sheppard DC, Viscoli C, Warris A, Donnelly JP.

Drug Resist Updat. 2015 Jul-Aug;21-22:30-40. doi: 10.1016/j.drup.2015.08.001. Epub 2015 Aug 7.

47.

Drug-interactions of azole antifungals with selected immunosuppressants in transplant patients: strategies for optimal management in clinical practice.

Lempers VJ, Martial LC, Schreuder MF, Blijlevens NM, Burger DM, Aarnoutse RE, Brüggemann RJ.

Curr Opin Pharmacol. 2015 Oct;24:38-44. doi: 10.1016/j.coph.2015.07.002. Epub 2015 Jul 25. Review.

PMID:
26218924
48.

Fundament and Prerequisites for the Application of an Antifungal TDM Service.

Brüggemann RJ, Aarnoutse RE.

Curr Fungal Infect Rep. 2015;9(2):122-129. Review.

49.

Altered Micafungin Pharmacokinetics in Intensive Care Unit Patients.

Lempers VJ, Schouten JA, Hunfeld NG, Colbers A, van Leeuwen HJ, Burger DM, Verweij PE, Pickkers P, Brüggemann RJ.

Antimicrob Agents Chemother. 2015 Aug;59(8):4403-9. doi: 10.1128/AAC.00623-15. Epub 2015 May 11.

50.

Impact of special patient populations on the pharmacokinetics of echinocandins.

Muilwijk EW, Lempers VJ, Burger DM, Warris A, Pickkers P, Aarnoutse RE, Brüggemann RJ.

Expert Rev Anti Infect Ther. 2015 Jun;13(6):799-815. doi: 10.1586/14787210.2015.1028366. Epub 2015 May 6. Review.

PMID:
25947367

Supplemental Content

Loading ...
Support Center